medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

Potential molecular targets of statins in the prevention of hepatocarcinogenesis

Ridruejo E, Romero-Caími G, Obregón MJ, Kleiman PD, Alvarez L

Language: English
References: 34
Page: 490-500
PDF size: 381.40 Kb.


ABSTRACT

Introduction and aim. Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins, may reduce the incidence of various tumors, including HCC. Antitumoral activities may be mediated by changes in transforming growth factor-beta (TGF-β1) and thyroid hormones (TH) regulation. Aim. The aim of our study is to establish the statins mechanism of action and the potential key molecules involved in an in vivo and in vitro HCC model. Materials and methods. We used two models: in vivo (in rats) using diethylnitrosamine (DEN) and hexachlorobenzene (HCB) to develop HCC. We analyzed cell proliferation parameters (proliferating cell nuclear antigen, PCNA) and cholesterol metabolism (hydroxy-methylglutaryl-CoA reductase, HMGCoAR). In vitro (Hep-G2 cells) we evaluated the effects of different doses of Atorvastatin (AT) and Simvastatin (SM) on HCB induced proliferation and analyzed proliferative parameters, cholesterol metabolism, TGF-β1 mRNA, c-Src and TH levels. Results. In vivo, we observed that cell proliferation significantly increased as well as cholesterol serum levels in rats treated with HCB. In vitro, we observed the same results on PCNA as in vivo. The statins prevented the increase in HMG-CoAR mRNA levels induced by HCB, reaching levels similar to controls at maximum doses: AT (30 µM), and SM (20 µM). Increases in PCNA, TGF-β1, and pc-Src, and decreases in deiodinase I mRNA levels induced by HCB were not observed when cells were pre-treated with AT and SM at maximum doses. Conclusion. Statins can prevent the proliferative HCB effects on Hep-G2 cells. TGF-β1, c-Src and TH may be the statins molecular targets in hepatocarcinogenesis.


REFERENCES

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin 2011; 61: 69-90.

  2. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-26.

  3. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012; 39: 486-92.

  4. Goodman M, Cook-Wiens G , Sundaram V, Jeon CY. Cancer Epidemiol Biomarkers Prev. Statin Use and Survival with Early- Stage Hepatocellular Carcinoma 2016; 25: 686-92.

  5. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.

  6. Pisanti S, Picardi P, Ciaglia E, D'Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res 2014; 88: 84-98.

  7. Bonovas S. Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes? Drugs 2014; 74: 1841-8.

  8. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 2016; 64: 47-57.

  9. Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol 2015; 63: 1190-7.

  10. Chen HH, Lin MC, Muo CH, Yeh SY, Sung FC, Kao CH. Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia. Medicine (Baltimore) 2015; 94: e1013.

  11. McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, Sahasrabuddhe VV. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst 2015; 107: pii: djv009.

  12. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-30.

  13. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, Yood MU, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol 2014; 38: 523-7.

  14. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013; 28: 485-92.

  15. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-21.

  16. Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open 2014; 4: e005399.

  17. Zhong GC, Liu Y, Ye YY, Hao FB, Wang K, Gong JP. Metaanalysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep 2016; 6: 26256.

  18. Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 2015; 62: 18-23.

  19. Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2015; 63: 1111-7.

  20. Matusewicz L, Meissner J, Toporkiewicz M, Sikorski AF. The effect of statins on cancer cells-review. Tumour Biol 2015; 36: 4889-904.

  21. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011; 71: 2286-97.

  22. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol 2014; 82: 263-74.

  23. Sato M, Kawai-Kowase K, Sato H, Oyama Y, Kanai H, Ohyama Y, Suga T, et al. c-Src and Hydrogen Peroxide Mediate Transforming Growth Factor- 1-Induced Smooth Muscle Cell-Gene Expression in 10T1/2 Cells. Arterioscler Thromb Vasc Biol 2005; 25: 341-7.

  24. Gustafson DL, Long ME, Thomas RS, Benjamin SA, Yang RS. Comparative hepatocarcinogenicity of hexachlorobenzene, pentachlorobenzene, 1,2,4,5-tetrachlorobenzene, and 1,4-dichlorobenzene: application of a medium-term liver focus bioassay and molecular and cellular indices. Toxicol Sci 2000; 53: 245-52.

  25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.

  26. de Tomaso Portaz AC, Caimi GR, Sánchez M, Chiappini F, Randi AS, Kleiman de Pisarev DL, Alvarez L. Hexachlorobenzene induces cell proliferation, and aryl hydrocarbon receptor expression (AhR) in rat liver preneoplastic foci, and in the human hepatoma cell line HepG2. AhR is a mediator of ERK1/2 signaling, and cell cycle regulation in HCBtreated HepG2 cells. Toxicology 2015; 336: 36-47.

  27. Sandoval-Usme MC, Umaña-Pérez A, Guerra B, Hernández- Perera O, García-Castellano JM3, Fernández-Pérez L, Sánchez-Gómez M. Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells. PLoS One 2014; 9: e87769.

  28. Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, Mazar IG, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012; 92: 1440-50.

  29. Ridruejo E, Romero Caimi G, Obregon MJ, Randi A, Mando OG, Kleiman de Pisarev D, Alvarez L. Potential role of TGF- ?1 and type III Deiodinase in hepatocarcinogenesis. In press

  30. Fan Z, Jiang H, Wang Z, Qu J. Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-?1 by attenuating the upregulation of SphK1. Oncol Rep 2016; 36: 1016-22.

  31. Shang L, Jia SS, Jiang HM, Wang H, Xu WH, Lv CJ. Simvastatin downregulates expression of TGF-?RII and inhibits proliferation of A549 cells via ERK. Tumour Biol 2015; 36: 4819-24.

  32. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23: 38-89.

  33. Ambroziak M1, Pachucki J, Stachlewska-Nasfeter E, Nauman J, Nauman A. Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 2005; 15: 1137-46.

  34. Park SS, Eom YW, Kim EH, Lee JH, Min DS, Kim S, Kim SJ, Choi KS. Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene 2004; 23: 6272-81.




2020     |     www.medigraphic.com